-
- TRL (Technology readiness level) -
-
- Titre METHOD FOR INCREASING THE POOL OF NGN3+ ENDOCRINE PROGENITOR CELLS AND PANCREATIC ENDOCRINE CELL MASS
- Description Controlling glycemia with insulinotherapy is a challenge that diabetic patients face every day. Moreover, insulinotherapy is not a curative therapy by any means. This line of treatment is only palliative and presents many limitations for the fine control of blood sugar levels. Uncontrolled blood sugar levels can result in serious damages to the eyes, nerves and kidneys of diabetic patients. However, pancreatic islets transplantation provides an alternative therapeutic option that would make perfect control of glycemia possible. As such, pancreatic cell therapy is an appropriate and effective solution for the treatment of type 1 diabetes.
The technology relies on the ability of K-ATP channels to regulate the secretion of insulin and the differentiation of α and β pancreatic cell. The technology is a method of cell therapy that involves in vitro stem cell differentiation into endocrine pancreatic cells. The stem cell differentiation is triggered by glibenclamide, a K-ATP channel inhibitor.
- Bénéfices Method that improves the efficiency of pancreatic cell production.
Large amounts of newly differentiated endocrine pancreatic cells can subsequently be transplanted in diabetic patients.
- Nouveauté New method for optimizing the production of pancreatic cells for cell therapy in diabetes
- Mots clés Diabetes, Pancreas, Pancreatic islets, Insulin, Cell therapy
- Secteurs Health
